



(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/US2024/032915

(22) International Filing Date:
07 June 2024 (07.06.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/506,911 08 June 2023 (08.06.2023) US

(71) Applicant: **XENTRIA, INC.** [US/US]; 2071 North Southport Ave., Suite 201, Chicago, Illinois 60614 (US).

(72) Inventors: **MATTHEWS, Thomas**; 2071 North Southport Ave., Suite 201, Chicago, Illinois 60614 (US). **SWART, Kenneth**; 2071 North Southport Ave., Suite 201, Chicago, Illinois 60614 (US).

(74) Agent: **FISCHER, Julie** et al.; Perkins Coie LLP, P.O. Box 1247, Seattle, Washington 98111-1247 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS FOR DETECTING A NEUTRALIZING ANTIBODY (NAB) AGAINST AN ANTI-TNF ALPHA ANTIBODY




FIG. 1

(57) Abstract: The present technology comprises methods for detecting a neutralizing antibody (NAb) against a target antibody. In some embodiments, the target antibody comprises an anti-Tumor Necrosis Factor-alpha (TNFα) antibody. In some embodiments, the target antibody comprises SEQ ID NO: 9-11 or 15-17 and SEQ ID NOs: 12-14 or 18-20. The present technology further comprises kits for performing the methods of the present technology.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*